ALL-REMOTE COMPANY/WILMINGTON, Del., November 22, 2024--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been selected by The Software Report as one of the "Top 100 Software Companies of 2024." The annual program evaluates companies based on a range of criteria, including product functionality, customer satisfaction, corporate reputation, innovative capabilities, organizational depth, ESG involvement and long-term viability. This is the third consecutive year Phreesia has been named to the list.
"We are proud once again to be recognized as a leader in SaaS innovation," said Phreesia CEO Chaim Indig. "This honor reflects Phreesia’s dedication to investing in products that help drive better health outcomes. We remain committed to making care easier every day and transforming the healthcare experience for both patients and providers."
In the announcement, The Software Report describes its list of honored companies as those that "are making a major impact on the software industry" in 2024. Phreesia is ranked 11 out of the 100 companies, up four spots from 2023. Other awardees this year include Hootsuite, Celigo and Enable.
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241122281765/en/
Contacts
Media Contact:
Nicole Gist
nicole.gist@phreesia.com
407-760-6274
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。